Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors ...

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat type 2 diabetes and obesity, seems to ...

Orforglipron stands out because it is a small-molecule, nonpeptide GLP-1 receptor agonist that can be taken orally, avoiding ...

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with ...

Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Pharmaceutical companies are racing to develop a GLP-1 weight-loss drug in pill form. Novo Nordisk says its oral semaglutide pill led to "significant weight loss" in a trial.

Makers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, are close to releasing pills taken daily to help shed pounds as an alternative to weekly injections.

Novo Nordisk › Novo Nordisk's (NYSE: NVO) leading medications have been hot discussion topics for years. Many Americans might ...

As a potential first-in-class, AI-designed oral GLP-1 receptor agonist (GLP-1RA), MDR-001 represents a breakthrough in drug discovery, demonstrating how AI can reshape traditional R&D pathways and ...

A new type of weight loss jab could tackle obesity without people needing to change their eating habits, experts have claimed ...

Beijing QL Biopharmaceutical has shared phase 2 data on its once-monthly GLP-1 candidate, providing early evidence that the ...

The results of this landmark trial are particularly significant, as oral therapies for obesity could improve both access to ...